Risk factors for infections with multidrug‐resistant <i>Pseudomonas aeruginosa</i> in patients with cancer

Abstract

Carbapenems may need to be used more judiciously as first-line empirical therapy for cancer patients with prior pseudomonal infection or chronic obstructive pulmonary disease who require hospitalization, and alternative, antipseudomonal antibiotic regimens may need to be considered, especially in this patient population.